This dual-sgRNA strategy with an HDR template greatly enhances CRISPR/Cas9 gene-editing efficiency to knockout PD-L1 in U87 cells, and was confirmed to knockout PD-L1 in human breasts cancer cells. This evidence concerns the gene CD274 and medical procedure.